Controlled Substances - As enacted, authorizes additional healthcare providers to directly administer buprenorphine mono or buprenorphine without the use of naloxone; adds that prescribing a buprenorphine product to nursing mother or prescribing an injectable mono product does not restrict certain healthcare providers from prescribing a buprenorphine product for the treatment of opioid use disorder without naloxone. - Amends TCA Title 53, Chapter 11.

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 1 History 14 Sponsors

No summary has been published for this bill. The full text is on the Bill text tab.

Chamber: Senate
Introduced: Jan 21, 2026
Last action: Apr 24, 2026 — Comp. became Pub. Ch. 753
Session: 114
Momentum: 33 · Low

PASSAGE PROBABILITY

25.3% Uncertain

Why this number

Stage base In Committee — base rate 51%, measured from TN's completed sessions
Momentum -4 33/100 from the pace of recorded action
Time since last action -22 171 days quiet

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.